Vastagbélrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 6
• KRAS 56
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Novel macrophage repolarization therapy for colorectal cancer

  Panorama Research, Inc.· Sunnyvale, Egyesült Államok· 387 240 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIAID · R01

  Impact of bacterial phenotypic variation on phage resistance

  Institute for Systems Biology· Seattle, Egyesült Államok· 874 085 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, Egyesült Államok· 762 815 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NCI · K99

  Developing and Piloting a Multilevel Intervention to Address Nutritional Needs in the Outpatient Oncology Setting

  Yale University· New Haven, Egyesült Államok· 168 290 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R01

  The role of IL-9 in gastric metaplasia and carcinogenesis

  Saint Louis University· Saint Louis, Egyesült Államok· 2 541 122 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spanyolország· EU contribution 194 075 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 217 965 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Ausztria· EU contribution 4 281 580 EUR· until 2031. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 990 running projects, newest first. Listed amounts together: 548,0 M USD + 233,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

  NCT06690281· National Cancer Institute (NCI)· Frissítve: 2025. szept. 11.

  “PI left NIH.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

  NCT04853043· University of Utah· Frissítve: 2025. máj. 6.

  “PI Determination - Slow recruitment, funding concerns, poor response to treatment”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  NCT05877599· AstraZeneca· Forrás

• Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

  NCT04767984· Northwestern University· Forrás

• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

  NCT06690281· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 134
• Organoids 108
• Mendelian Randomization Analysis 51
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 30
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 120
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 318
• Genome-Wide Association Study 66

• Targeting the gut-tumor axis: probiotic therapy as an adjunct strategy in colorectal cancer treatment.

  Front Cell Infect Microbiol, 2026. okt.

• Receptor-Side Neuroimmune Remodeling in IBD: Participant-Level Associations with Metabolite-Sensing Programs and Colorectal Neoplasia Context.

  Int J Mol Sci, 2026. okt.

• Comparative Metabolomics Identifies Diterpene-Rich Marine Macroalgae with Potent Antiproliferative Activity Against Colorectal Cancer Cells.

  Mar Drugs, 2026. szept.

• Effects of dietary fucoidan and exercise on the gut microbiome, fecal metabolome, and tumor-related responses in a murine colorectal cancer model.

  Front Cell Infect Microbiol, 2026. szept.

• Laser-induced graphene arrays for high-throughput metabolic profiling reveal serum metabolic alterations in colon cancer.

  Talanta, 2026. szept.

• A robustness-first cross-disease framework supports a candidate shared microbial redox axis and disease-specific metabolic divergence in colorectal cancer, Crohn's disease, and liver cirrhosis.

  mSystems, 2026. szept.

• Urinary metabolomics may improve prediction of overall survival beyond tumor stage in colorectal cancer: results from the ColoCare study.

  Metabolomics, 2026. szept.

• Development of a Large-Scale Serum Metabolome Relative Quantitative Method and Application for Metabolic Traits of Colon Cancer.

  J Proteome Res, 2026. szept.

• Comprehensive analysis of metabolomics and transcriptomics of radiation-induced rectal injury.

  Genomics, 2026. szept.

• Integrated Metabolomic and Metagenomic Profiling Reveals Distinct Microbial-Metabolic Signatures in the Adenoma-Carcinoma Sequence of Colorectal Cancer.

  Biomed Chromatogr, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.